Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In
Dear All (and with thanks to ATMF’s Damiano de Felice for co-authoring this newsletter), Last week, the team at ATMF (Access to Medicine Foundation) released a 3rd update to the AMR Benchmark series that they started in 2018. For those not familiar with the ATMF, its independent analyses (all its funding is from governments or private
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Exciting and intriguing news to share about PASTEUR (and see this 16 June 2021 newsletter if you need a refresher on the ideas behind PASTEUR)! A new draft is now circulating with the intent of attaching it to a larger bill that is on track
Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive
Dear All (and note the related 29 Apr 2021 newsletter), As was discussed at length in the recent Wellcome Trust-sponsored analysis of the AMR-related needs for the coming decades (see this newsletter), it is critical that we build and maintain momentum around AMR-focused work. As a big part of that revolves around being visible in
Dear All, As was discussed in these prior newsletters, the EU has announced an ambitious Pharmaceutical Strategy with initiatives that include development of Pull incentives for antimicrobials among a number of other topics (see the 28 Nov 2020 newsletter for the full list): 28 Nov 2020 (a general announcement) 29 Apr 2021 (comments by Stella Kyriakides) 24 Jun 2021 (RFPs
Dear All, The US Office of the Assistant Secretary for Preparedness & Response (ASPR) is looking for comments on the 2023-2026 National Health Security Strategy (NHSS). They would like input from stakeholders in public health, healthcare, emergency management, national security, non-governmental organizations, academia, and private industry. Their specific questions to consider are: What are the most critical national health
Dear All, Continuing on the theme of helping countries develop their own national action plans, WHO released the “WHO implementation handbook for national action plans on antimicrobial resistance: guidance for the human health sector“. The handbook has some great infographics like the one below and will shortly be translated into French, Spanish, and Russian. There
Dear All, WHO continues on their streak of seeking support for their AMR-related work! Today we have a posting by the Tripartite Joint Secretariat on Antimicrobial Resistance (AMR) of a consultancy opening for an 11-month project that would support development of multisectoral guidance(s) on development and strengthening of the coordination mechanisms and governance structures for addressing AMR. Full details
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust